Novartis drug Tasigna recommended for approval in European Union for newly diagnosed Ph+ chronic myeloid leukemia
The Committee for Medicinal Products for Human Use (CHMP) recommended approval of Tasigna in the first-line indication based on a pivotal Phase III clinical trial in which Tasigna surpassed Glivec® (imatinib) in key measures of treatment efficacy. In the study, Tasigna was found superior to Glivec in achieving higher rates of both major molecular and complete cytogenetic response and in delaying cancer progression. The data were first published in the June 17 issue of The New England Journal of Medicine and were confirmed by 18-month median follow-up data presented at the 2010 annual meeting of the American Society of Clinical Oncology held in June.
"We are glad that the development of Tasigna may result in a potential new treatment option for newly diagnosed CML patients seeking effective means of preventing disease progression," said Alessandro Riva, Global Head, Oncology Development & Medical Affairs, Novartis Oncology. "Following this positive opinion from CHMP, we look forward to working with regulatory authorities to bring Tasigna to clinical use in the first-line setting as soon as possible."
The European Commission generally follows the recommendations of the CHMP and delivers its final decision within three months. The decision will be applicable to all 27 European Union (EU) member states plus Iceland and Norway. In total, approximately 46,000 people in the EU are affected by CML, a life-threatening blood cancer.
The US Food and Drug Administration (FDA) and Swiss health authority Swissmedic have already approved Tasigna for newly diagnosed Ph+ CML. Regulatory submissions are also under way in Japan and worldwide.
Other news from the department price development
Are the high prices of cancer drugs justified?
Does the cost correspond to the particular drug’s effectiveness in combating the disease?
Significant overall survival benefit observed with radium 223 in patients with castration-resistant prostate cancer
Medivir Announces Positive 48-week Interim Data from TMC435 Hepatitis C Phase 2b ASPIRE Study in Treatment-Experienced Genotype-1 Patients
BASF Increases Prices for Nature-Identical Carotenoids for Human and Animal Nutrition, Excluding Astaxanthin
Genzyme and Isis Report Results of Two Phase 3 Trials of Mipomersen
Studies Meet Primary Endpoints with 36 and 37 Percent LDL-C Reductions in Severe Hypercholesterolemia and High-Risk Patients
Roche's weekly taspoglutide meets primary end-point in key Phase III study
Taspoglutide demonstrates superiority in HbA1c change versus placebo as add-on to metformin and pioglitazone
Most read news
Cells with an ear for music release insulin
"Anti-obesity drugs" normalises brain in obesity
Anti-obesity drug improves associative learning in people with obesity
Microbe of the Year 2023: Bacillus subtilis – for health and technology
Younger generation gets sick earlier and more often than older generation
How sleep deprivation can harm the brain
Sleep deprivation decreases the amount of a factor that protects neurons
A whole new order of bacteria could hold the key to improving biogas production
The discovery was made by researchers from Germany, Spain and the Netherlands
How to inactivate common cold viruses
In the cold season, cold viruses are everywhere. But we can do something about it
New approach to testing for long Covid
Blood vessels in the eye altered with persistent coronavirus symptoms
How minimal genetic differences can turn healthy food into a deadly danger
More news from our other portals
Major breakthrough in the development of electric vehicle batteries
Blender Bites launches at Walmart USA
The products are to be introduced in about 1,600 stores across the country
Benchtop NMR spectroscopy can accurately analyse pyrolysis oils
Clean water from fog
Research shows table salt could be the secret ingredient for better chemical recycling
Table salt as the key to the plastics recycling revolution?
Green, sweet and crisp - New apple variety Pia41 approved
The apple bred at the Julius Kühn Institute receives variety protection
Graphene discovery could help generate hydrogen cheaply and sustainably
Microscopic insights into electrochemical interfaces
Sugar: Small increase in production despite record prices
EU sugar market more than in need of reform to keep medium-sized processing companies competitive
Scientists use quantum device to slow down simulated chemical reaction 100 billion times
What happens in femtoseconds in nature can now be observed in milliseconds in the lab
Green methanol for shipping and industry: € 10.4 Mio. for the "Leuna100" project
New battery holds promise for green energy
Redox-flow battery eliminates costly and inefficient membrane
Fondant under the magnifying glass
Leipzig-based start-up converts CO₂ into green chemicals with patented plasma catalysis
CO₂ recycling as a useful complement to carbon capture and storage
A microchip for Parmigiano Reggiano cheese
Cleaning water with ‘smart rust’ and magnets
New method for pollutants such as crude oil, glyphosate, microplastics and hormones
A Second Life for Electric Car Batteries
Scientists develop a decision model for retired lithium-ion batteries